Home » Stocks » MOR

MorphoSys AG (MOR)

Stock Price: $25.21 USD -0.49 (-1.91%)
Updated Oct 28, 2020 11:32 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 3.30B
Revenue (ttm) 293.21M
Net Income (ttm) 67.94M
Shares Out 130.87M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $25.21
Previous Close $25.70
Change ($) -0.49
Change (%) -1.91%
Day's Open 25.02
Day's Range 24.94 - 25.37
Day's Volume 20,363
52-Week Range 18.21 - 37.96

More Stats

Market Cap 3.30B
Enterprise Value 3.02B
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 130.87M
Float n/a
EPS (basic) -0.99
EPS (diluted) -0.26
FCF / Share 0.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 3.34%
Payout Ratio n/a
Shares Short 272,445
Short Ratio 5.68
Short % of Float n/a
Beta 1.02
PE Ratio n/a
Forward PE 322.58
P/FCF Ratio 29.96
PS Ratio 11.25
PB Ratio 4.76
Revenue 293.21M
Operating Income 76.36M
Net Income 67.94M
Free Cash Flow 110.13M
Net Cash 274.82M
Net Cash / Share 2.10
Gross Margin 20.35%
Operating Margin 26.04%
Profit Margin 23.20%
FCF Margin 37.56%
ROA 4.92%
ROE 18.81%
ROIC 11.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (16)

Buy 11
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(57.00% upside)
Current: $25.21
Target: 39.58
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-6.13%14.45%34.27%-
Gross Profit59.6774.6566.7949.74
Operating Income-108-60.06-67.06-60.10
Net Income-103-56.17-69.83-60.38
Shares Outstanding31.6131.3428.9526.44
Earnings Per Share-0.82-0.45-0.60-0.57
Operating Cash Flow-80.14-33.27-38.45-46.62
Capital Expenditures-3.08-1.79-1.32-2.50
Free Cash Flow-83.22-35.06-39.76-49.11
Cash & Equivalents273359312280
Total Debt42.570.070.090.22
Net Cash / Debt230359312280
Book Value395488359415
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MorphoSys AG
Country Germany
Employees 572
CEO Jean-Paul Kress

Stock Information

Ticker Symbol MOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MOR
IPO Date March 9, 1999


MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.